ESMO - Eur. Oncology

@myESMO

The European Society for Medical Oncology (ESMO) supports oncology professionals in providing cancer patients with the most effective treatment and care.

Lugano - Switzerland
Vrijeme pridruživanja: kolovoz 2009.

Tweetovi

Blokirali ste korisnika/cu @myESMO

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @myESMO

  1. Prikvačeni tweet
    4. velj

    : 'We need to fight for and state that no limitations cannot be challenged… and create more equity in the future in the way that we treat worldwide, delivering to patients optimal cancer care'

    Poništi
  2. proslijedio/la je Tweet
    prije 1 sat

    Javier Martin presenting sunitinib + nivolumab and axitinib + pembrolizumab for patients Sarcoma

    Poništi
  3. proslijedio/la je Tweet
    prije 2 sata

    Lee Helman discussing the potential antigens that may be used to develop cellular therapy against cells. ⁦⁩ sarcoma

    Poništi
  4. proslijedio/la je Tweet
    prije 3 sata

    Deadline reminder TODAY 21:00 CET- Have you finalised your application to attend a week-long course designed to educate and train early-career investigators in the best practices of ? Apply NOW

    Poništi
  5. prije 4 sata

    The outlines steps to save 7 million lives from . The ‘WHO Report on Cancer: setting priorities, investing wisely & providing care for all’ also mentions two ESMO resources fundamental to support accessible & help commitment

    Poništi
  6. proslijedio/la je Tweet
    prije 5 sati

    Systemic therapy landscape for patients with tumor ⁦

    Poništi
  7. proslijedio/la je Tweet
    prije 8 sati

    General guide to estimating risk of recurrence after resection of . Helpful in discussions regarding neoadjuvant/adjuvant imatinib. ⁦

    Poništi
  8. proslijedio/la je Tweet
    4. velj

    Watch out! -fused also in the bones. Although more common in STS with complex genomics and WT GIST, it seems they can be found essentially across all phenotypes.

    Poništi
  9. proslijedio/la je Tweet

    ...and from “his take” us as young oncologists should take motivation for moving forward research in . Inspiring second day at ESMO sarcoma and GIST

    Poništi
  10. proslijedio/la je Tweet

    ⁩ : ~50% of are , , or UPS. The other subtypes are double rare ⁦

    Poništi
  11. proslijedio/la je Tweet
    4. velj

    The manuscript on the global consensus about management of desmoid tumor by patients, researchers and physiscians is finally out! Thanks to all!

    Poništi
  12. proslijedio/la je Tweet
    4. velj

    Excellent meeting with on how to act united towards access to affordable innovative cancer medicines - I am firmly committed to people-centred cancer prevention and care across the European Region on this , and every day 👉

    Poništi
  13. proslijedio/la je Tweet
    4. velj

    I can’t believe it has been almost two years… 🗣: Check out the „Leaders Generation Programme“. For me, it has been an inspiring and truly transformative experience🚀 👇

    Poništi
  14. proslijedio/la je Tweet
    4. velj

    World cancer day: let's fight this devastating disease. Let's improve cure rates through clinical research and by listening to our patient's needs

    Poništi
  15. 4. velj

    : 'Let's get out of comfort zones and close boundaries so we can collectively assess and develop new, innovative options for patients'

    Poništi
  16. proslijedio/la je Tweet
    4. velj

    ⁩ highlighting successful in : Our phase 2 Axi-Pembro by ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ ⁦⁩ Sarcoma ⁦

    Poništi
  17. proslijedio/la je Tweet
    4. velj

    MPNST-like spindle cell neoplasms May have molecular aberration in NTRK or RAF. Raises therapeutic implications. ⁦

    Poništi
  18. proslijedio/la je Tweet
    4. velj

    Very wide morphological spectrum of EWSR1 translocated cancers including but not limited to

    Poništi
  19. proslijedio/la je Tweet
    4. velj

    Frank Tirode: molecular classification of begins with expert pathologist review. ⁦⁩ Sarcoma

    Poništi
  20. proslijedio/la je Tweet
    3. velj

    Immune-PDX mice models as a potential biomarker to support clinical decision making or to predict relapse in patients with melanoma

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·